Related Experiment Video
Updated: Oct 25, 2025
05:45
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024
2.3K
[Chordoid glioma: a clinicopathological study]
L M Wang1, L W Shao2, B Cheng3
1Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology
|August 3, 2021
Summary
Chordoid gliomas exhibit distinct clinical and pathological traits. PRKCA gene mutations are identified as potential diagnostic biomarkers and targets for future chordoid glioma therapies.
Area of Science:
- Neuropathology
- Molecular Oncology
Background:
- Chordoid glioma is a rare brain tumor with distinctive histological features.
- Understanding its clinicopathological and molecular characteristics is crucial for diagnosis and treatment.
Purpose of the Study:
- To analyze the clinicopathological, imaging, and molecular features of chordoid glioma.
- To identify potential diagnostic biomarkers and therapeutic targets for chordoid glioma.
Main Methods:
- Retrospective analysis of 12 chordoid glioma cases.
- Review of clinical, imaging, pathological, and molecular data.
- Immunohistochemistry and Sanger sequencing for gene mutation analysis (PRKCA, IDH).
Main Results:
- Chordoid gliomas typically present with headache or vision loss, often located in the third ventricle.
- All cases showed characteristic morphology and immunohistochemical profiles (GFAP, vimentin, TTF1, CD34, CKpan, EMA).
- PRKCA gene D463H mutation was found in 8/9 cases, while IDH mutations were absent.
Conclusions:
- Chordoid gliomas possess unique clinical and histopathological features.
- PRKCA gene mutation serves as a potential diagnostic biomarker for chordoid glioma.
- PRKCA mutation may guide future targeted therapies for chordoid glioma.
